ClinicalTrials.gg
CompletedNCT01349335Updated Oct 12, 2012

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

A Phase 2 interventional study of Tolvaptan and Tolvaptan in Ascites and Hepatic Cirrhosis, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-10-12.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing tolvaptan in Ascites — none open to participants now, none under way, none of them phase 3. Tolvaptan · Ascites.

Enrollment
2nd of 10
180 · median 78
Started
2009
with 3 others
Phase 2
2 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Otsuka Beijing Research Institute

Among the 10 studies testing tolvaptan in Ascites, this one is the 2nd largest by enrollment, is one of 4 that started in 2009, is one of 2 in phase 2, and was the 4th registered.

Ascites

247 studies on the registry are indexed under Ascites; 56 are open to participants now.

Browse Ascites studies →

Open to participants now

None of the 10 studies testing tolvaptan in Ascites is open now. The open studies under Ascites, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 40 Ascites studies recruiting now, 21 (53%) set no upper age limit and 12 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing tolvaptan in Ascites as a file.
02

Study summary

To observe the safety/efficacy of tolvaptan for treatment of patients with hepatic cirrhosis with ascites and exploring the dosage-effect relations of the drug.

Read the detailed description

Tolvaptan is able to exert hydragogue diuretic effects (water diuresis) via inhibition of water reabsorption by renal collecting ducts without corresponding increase in electrolyte excretion. It has been confirmed that tolvaptan is able to increase urine volume without any adverse effects on renal functions.

03

Conditions studied

  • Ascites
  • Hepatic Cirrhosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. hepatic cirrhosis patients after 7days treatment of loop diuretics and aldosterone antagonist but still with ascites
  2. Hospitalized patients or those who can be hospitalized in this trial between observation period and posttherapeutic observation (Visits at clinic will be allowed after day 8);
  3. During the observation period (-3 day to -1 day ), subjects whose body weight difference fall within ±1.0 kg range 2 days (day-2 and day -1) prior to initiation of trial drug treatment;
  4. Ages: ≥18 and ≤75 years of age;
  5. Genders: men or women;
  6. Signed the Form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with the following diseases, complications or symptoms:

    • Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher);
    • Malignant ascites;
    • Uncontrolled spontaneous bacterial peritonitis;
    • Patients are likely to experience alimentary tract hemorrhage during the trial;
    • Heart failure ( cardiac function scale Note 2) stages 3 and 4);
    • Anuria (daily urine volume below 100mL);
    • Dysuria resulting from urethral stricture, calculus and tumors.
  2. Patients with the following medical history:

    • Alimentary tract hemorrhage within 10 days prior to screening;
    • Cerebrovascular accident within 1 month prior to screening;
    • Gout attack within 1 month prior to screening;
    • Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride)
  3. Systolic pressure below 90mmHg at screening;
  4. Patients with the following abnormalities in laboratory examinations at screening:

    Serum creatinine exceeds 2.5X , serum Na+>145mmol/L (or exceeds upper limits of normal), serum K+>5.5mmol/L, uric acid>8.0mg/dL (476μmol/L), scale greater than 12.

  5. Patients cannot take drugs orally;
  6. Pregnant or breast-feeding patients or women at child-bearing ages without taking acceptable measures;
  7. Patients received albumin or other blood preparations within 4 days prior to trial drug administration;
  8. Patients participated in clinical trials of other drugs within 1 month prior to screening;
  9. Patients participated in tolvaptan trials and took tolvaptan previously;
  10. Patients are unsuitable to participate in this trial in investigators' opinion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    1. tolvaptan

    15 mg, P.O., Qd, for 7 days,

    Drug: Tolvaptan

  • Experimental
    2 tolvaptan

    30 mg, P.O., Qd, for 7 days,

    Drug: Tolvaptan

  • Experimental
    3. Placebo

    30mg,P.O.,Qd, for 7 days.

    Drug: placebo

Interventions

  • tablet, 15 mg, Qd, for 7 days

    Also known as: SAMSCA

  • tablet, 30 mg, Qd, 7 days

    Also known as: SAMSCA

  • Drugplacebo

    tablet, 30 mg, Qd, 7days.

    Also known as: blank tablet

06

What researchers measure

Primary outcomes

  1. Body weight changes after 7 days of treatment (quantity of changes)

    Time frame: from day1 to day7

Secondary outcomes

  1. Body weight change after 4 days of treatment (quantity of changes)

    Time frame: from day1 to day4

  2. Waist circumference after 4 and 7 days of treatment (quantity and rate of changes)

    Time frame: from day1 to day7

07

Study locations

1 site
  • Renji hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200001, China
08

References and documents

Publications

  • Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol. 2018 Sep 4;18(1):137. doi: 10.1186/s12876-018-0857-0. PubMed 30180806 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jan 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2010
First posted
May 6, 2011
Start
Apr 2009
Primary completionActual
Jan 2010
CompletionActual
Apr 2010
Last update
Oct 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01349335
Responsible party
Sponsor
First posted
May 6, 2011
Start date
Apr 2009
Primary completion
Jan 2010
Completion
Apr 2010
Last update
Oct 12, 2012

Study contacts

Minde Zeng
principal investigator · RenJi Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion